PMI
13.6.2019 12:39:03 CEST | Business Wire | Press release
Philip Morris International (PMI) today launches unsmokeyourworld.com , a new online hub for those that want to un smoke themselves or their loved ones, their communities, or the world. The website aims to provide an inspiring and engaging place to help people kick-start their smoke-free journeys. The best way to un smoke is to quit cigarettes and nicotine completely. For adult smokers that don’t the next best option is to switch to a better alternative.
A new survey conducted by Povaddo, commissioned by PMI, shows the potential to improve personal and social relationships by quitting cigarettes. Almost three-quarters—71 percent—of nonsmokers who are in a relationship with a smoking partner said they have had disagreements with their partner because he/she smokes cigarettes. The results showed even higher levels of disagreement in Israel, Italy and Russia, with 80 percent or more stating they have argued with their partner over smoking.
| Have you ever had a disagreement or argument with your partner or spouse because he/she smokes cigarettes? | |||||||||||||
|
Yes |
Russia | U.K. | U.S. | Hong Kong | Israel | Italy | |||||||
| 82% | 63% | 63% | 67% | 80% | 87% | ||||||||
| Japan | Mexico | Australia | Brazil | Denmark | Germany | ||||||||
| 55% | 77% | 68% | 72% | 56% | 55% | ||||||||
| Base: former and never smokers with a partner that smokes | |||||||||||||
Smokers, however, were less likely to recognize the impact that smoking has on their relationships with loved ones, with just, on average, 36 percent of them acknowledging that smoking has caused arguments with their loved ones.
| My smoking causes arguments with loved ones: | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Strongly/ Somewhat agree | Russia | U.K. | U.S. | Hong Kong | Israel | Italy | |||||||||||||||||||||||||||||||||||||||||||||||||
| 38% | 32% | 32% | 42% | 43% | 43% | ||||||||||||||||||||||||||||||||||||||||||||||||||
| Japan | Mexico | Australia | Brazil | Denmark | Germany | ||||||||||||||||||||||||||||||||||||||||||||||||||
| 22% | 43% | 25% | 62% | 8% | 22% | ||||||||||||||||||||||||||||||||||||||||||||||||||
|
Base: current and occasional smokers.
Figures have been summed due to rounding |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||
“This research shows the scale of the task ahead to help smokers understand the positive impact that unsmoking could have on their relationships,” said Jacek Olczak, Chief Operating Officer, PMI. “We believe that this type of insight should be made known to smokers so they can engage in a conversation and understand the benefits of getting behind the #unsmoke movement.”
Aiming to unify communities toward a smoke-free world, PMI’s unsmokeyourworld.com is an online hub where adult smokers and those that care about them can discover more about ways to un smoke. The site shares stories of un smoke heroes describing their smoke-free journeys and encourages readers to share their own stories.
Olczak continues: “Change comes from communities uniting behind a positive conversation, which is why we have created this place for people to come together and hear each other’s stories for inspiration. This is an important new tool for adult smokers and those who care about them so they can access resources to inspire them to leave cigarettes behind.”
Interactive elements engage readers to understand the facts behind unsmoking and allows them to publicly get involved. Users can add an ‘Un smoke Your World’ overlay to any image they want so they can show support on social media. They can also download and share a selection of gifs to celebrate un smoke successes.
Since April 2019, over 115,000 digital #unsmokeyourworld actions have taken place across the globe—ranging from individuals supporting the campaign on social media to engaging with digital content. PMI’s is calling for people to take action and create a strong movement to an un smoked world. For more information visit, unsmokeyourworld.com .
About the Povaddo Survey
This survey was carried out 24
April-6 May, 2019, by Povaddo, a leading public opinion research firm,
on behalf of Philip Morris International. The survey fielded a total of
16,099 online interviews among general population adults 21-74 years of
age across 13 countries (Argentina, Australia, Brazil, Denmark, Germany,
Hong Kong, Israel, Italy, Japan, Mexico, Russia, United Kingdom and
United States). The survey carries an overall margin of error of +/- 1%
at the 95 percent confidence interval.
About #Unsmokeyourworld
PMI is transforming its business and
increasing awareness of the urgent need to become smoke-free as well as
awareness of better alternatives for smokers who would otherwise
continue to smoke. PMI is producing smoke-free products that are a
better choice for smokers than continued cigarette smoking and can
benefit public health.
#Unsmoke is a PMI initiative to speed up an historic change in public health. Through the #unsmoke movement, we want to bring together a community of people who can accelerate this change by becoming advocates of the message that for smokers who would otherwise continue to smoke, there are better alternatives to choose from.
#Unsmokeyourworld is a global conversation that inspires human stories—for the people, by the people.
About Philip Morris International
Delivering a Smoke-Free
Future Philip Morris International (PMI) is leading a transformation in
the tobacco industry to create a smoke-free future and ultimately
replace cigarettes with smoke-free products to the benefit of adults who
would otherwise continue to smoke, society, the company and its
shareholders. PMI is a leading international tobacco company engaged in
the manufacture and sale of cigarettes, smoke-free products and
associated electronic devices and accessories, and other
nicotine-containing products in markets outside the U.S. PMI is building
a future on a new category of smoke-free products that, while not
risk-free, are a much better choice than continuing to smoke. Through
multidisciplinary capabilities in product development, state-of-the-art
facilities and scientific substantiation, PMI aims to ensure that its
smoke-free products meet adult consumer preferences and rigorous
regulatory requirements. For more information, please visit http://www.pmi.com
and www.pmiscience.com
.
# # #
View source version on businesswire.com: https://www.businesswire.com/news/home/20190613005304/en/
Contact:
David Fraser Philip Morris International Media Office T. +41 (0)58 242 4500 E. david.fraser@pmi.com
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
SOLUM and Simbe Expand European Collaboration to Advance Intelligent Store Operations5.3.2026 08:00:00 CET | Press release
SOLUM (KOSPI: 248070) and Simbe announced the expansion of their strategic collaboration to further integrate autonomous store intelligence with SOLUM’s Newton Electronic Shelf Label (ESL) infrastructure across Europe. The collaboration was highlighted at EuroShop, where Simbe’s Store Intelligence™ platform was demonstrated live at the SOLUM booth. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260304620371/en/ SOLUM and Simbe announced the expansion of their strategic collaboration to further integrate autonomous store intelligence with SOLUM’s Newton Electronic Shelf Label (ESL) infrastructure across Europe. (Image: SOLUM) Simbe recently introduced Tally 4.0, the next generation of their autonomous shelf-scanning robot, reflecting the company’s continued evolution in retail shelf digitization, incorporating extended runtime, enhanced edge computing, and advanced vision capabilities. Designed to deliver deeper shelf coverag
Mosaic Clinical Technologies Announces FDA Breakthrough Device Designation for Cognita’s Generative AI Model for Radiology5.3.2026 08:00:00 CET | Press release
Breakthrough designation means Cognita™ will engage in prioritized interaction with FDA regarding clearance of device designed to help solve the radiology capacity bottleneck Mosaic Clinical Technologies™, a wholly-owned subsidiary of Radiology Partners, is pleased to announce that Cognita™, its AI business unit developing generative vision-language models (VLMs) for radiology, has received U.S. Food and Drug Administration (FDA) Breakthrough Device Designation for Cognita Chest X-Ray (CXR)™1 across multiple critical indications. Cognita CXR is an industry-first generative vision-language model designed to assist radiologists in the interpretation of chest X-rays and is the first radiology generative AI model, and one of very few radiology AI solutions, to be granted this designation2. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260304633206/en/ Cognita™ operates as the AI business unit of Mosaic Clinical Technologies™, a
Cielo Advances Resilient Remote Connectivity for Its Nationwide Payment Terminal Fleet With Thales5.3.2026 08:00:00 CET | Press release
Cielo, one of Brazil’s leading payment service providers, is piloting remote connectivity management for its point-of-sale (POS) terminals across the country, in partnership with Thales. By deploying Thales’s eSIM connectivity management platform based on the latest GSMA SGP.32 IoT standard, Cielo is accelerating its transition from manual, on-site SIM management to fully remote, secure and resilient connectivity. For Cielo, connectivity is mission critical. When payment terminals lose network access, transactions stop. To strengthen operational resilience and enhance merchant experience, Cielo is modernizing its connectivity architecture across its terminal fleet. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260304089321/en/ Cielo advances resilient remote connectivity for its nationwide payment terminal fleet with Thales. Using Thales’s eSIM technology as part of this strategy, Cielo can remotely switch mobile network op
GAIA and Daiichi Sankyo Europe Enter Exclusive Partnership to Launch Next-Generation Digital Therapeutic for Cardiovascular Care in Europe.5.3.2026 08:00:00 CET | Press release
GAIA, the pioneer in evidence-based digital therapeutics and Daiichi Sankyo Europe, today announced an exclusive strategic partnership to commercialize lipodia upon regulatory approval1. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260224658973/en/ Dr. Mario Weiss, Founder & CEO of GAIA AG This digital therapeutic is designed to support adults living with hypercholesterolemia. The comprehensive collaboration brings together GAIA’s long-standing expertise in developing clinically validated non-pharmacological interventions with Daiichi Sankyo’s highly scientific experience in cardiovascular risk management and health. Together, the partners - both members of the German Association of Research-Based Pharmaceutical Companies (vfa) - aim to address a persistent gap in chronic care: leveraging digital technologies to make a difference in patients’ lives by supporting sustainable, long-term behaviour change. Expanding Cardiovasc
Galderma Delivers Record 2025 Results With Net Sales of 5.207 Billion USD, up 17.7% at Constant Currency1, and Core EBITDA2 of 1.211 billion USD, Growing 18.9% at Constant Currency5.3.2026 07:00:00 CET | Press release
Ad hoc announcement pursuant to Art. 53 LR Galderma Group AG (SIX:GALD), the pure-play dermatology category leader, today announced its financial results for the full year 2025. Record net sales of 5,207 million USD, surpassing 5 billion USD in a year for the first time and representing 17.7% year-on-year growth on a constant currency1 basis, primarily driven by volume. Broad-based net sales growth, growing double-digits in both International markets and the U.S. Outperforming the market in each product category, with strong net sales growth in Injectable Aesthetics (11.5%), Dermatological Skincare (9.3%) and Therapeutic Dermatology (50.2%), all year-on-year at constant currency. Strong launch momentum across future growth drivers, including Nemluvio® (nemolizumab) delivering 452 million USD in net sales; Relfydess™ (RelabotulinumtoxinA) outperforming expectations in 17 International markets; Sculptra® gaining significant market share in its first year in China; and continued new produ
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
